Effect of trans-anetol (t-An) as nutritive addition to cytochrome P-450 containing system (MOS) of liver of rats was studied. It was shown, that t-An rendered inducing action to MOS, which depended on degree of action. It was established that simultaneous effect of t-An and mixture of polychlorinated diphenyles (sovol) modified inducing action of sovol to cytochrome P-450 system, Simultaneous effect of t-An and mixture of polychlorinated diphenyles increased hepatotoxic action of these xenobiotics.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Differential detoxification enzyme profiles in C-corn strain and R-rice strain of Spodoptera frugiperda by comparative genomic analysis: insights into host adaptation.
BMC Genomics
January 2025
Provincial Key Laboratory for Agricultural Pest Management of Mountainous Region, Institute of Entomology, Guizhou University, Guiyang, 550025, China.
Background: The fall armyworm (FAW) Spodoptera frugiperda, a highly invasive, polyphagous pest, poses a global agricultural threat. It has two strains, the C-corn and R-rice strains, each with distinct host preferences. This study compares detoxification enzyme gene families across these strains and related Spodoptera species to explore their adaptation to diverse host plant metabolites.
View Article and Find Full Text PDFCerebrotendinous xanthomatosis: A complex interplay between a clinically and genetically heterogeneous condition.
Eur J Neurol
January 2025
Brain and Mind Centre, University of Sydney, Camperdown, New South Wales, Australia.
Background And Purpose: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease characterized by abnormal bile acid synthesis. It often presents with systemic and neurological manifestations; however, atypical presentations can lead to significant diagnostic challenges. This case report highlights the diagnostic complexities and management considerations in a patient with an uncommon presentation of CTX.
View Article and Find Full Text PDFHow Uremic Toxins Alter Atorvastatin Disposition: Molecular Mechanisms of Inhibition of the Enzyme CYP3A4.
Balkan Med J
January 2025
Department of Clinical Pharmacy, China Pharmaceutical University, School of Basic Medicine and Clinical Pharmacy, Nanjing, China.
Article Synopsis
- Uremic patients accumulate protein-bound uremic toxins (PBUTs), which alter drug metabolism by affecting the environment around liver cells and CYP450 enzymes.
- The study found that specific PBUTs like indoxyl sulfate (IS) and hippurate (HA) significantly inhibit the metabolism of atorvastatin (ATV), with IS being the most impactful, reducing ATV metabolism by over 50%.
- Results showed that the expression of the enzyme CYP3A4, critical for drug metabolism, was downregulated in the presence of uremic serum, leading to decreased ATV uptake and excretion due to effects on related signaling pathways.
18 kDa TSPO targeting drives polarized human microglia towards a protective and restorative neurosteroidome profile.
Cell Mol Life Sci
January 2025
Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126, Pisa, Italy.
An aberrant pro-inflammatory microglia response has been associated with most neurodegenerative disorders. Identifying microglia druggable checkpoints to restore their physiological functions is an emerging challenge. Recent data have shown that microglia produce de novo neurosteroids, endogenous molecules exerting potent anti-inflammatory activity.
View Article and Find Full Text PDF[Precision Medicine for Patients with Renal Cell Carcinoma Based on Drug-metabolizing Enzyme Expression Levels].
Yakugaku Zasshi
January 2025
Department of Personalized Medicine and Preventive Healthcare Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University.
Notable advances have recently been achieved in drug therapies for renal cell carcinoma (RCC). Several tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have been approved for metastatic RCC (mRCC). The current first-line treatment for mRCC involves combination therapies using TKIs and ICIs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!